| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 5 | 2015 | 98 | 1.660 |
Why?
|
| Smallpox Vaccine | 5 | 2013 | 16 | 1.410 |
Why?
|
| Meningococcal Vaccines | 3 | 2021 | 22 | 1.160 |
Why?
|
| Epidural Abscess | 2 | 2018 | 9 | 1.100 |
Why?
|
| Anthrax | 8 | 2012 | 14 | 1.090 |
Why?
|
| Communicable Disease Control | 3 | 2015 | 42 | 0.980 |
Why?
|
| Meningitis, Meningococcal | 2 | 2014 | 8 | 0.800 |
Why?
|
| Personal Protective Equipment | 2 | 2020 | 32 | 0.790 |
Why?
|
| Quality Improvement | 2 | 2017 | 455 | 0.780 |
Why?
|
| Smallpox | 4 | 2009 | 10 | 0.700 |
Why?
|
| Meningococcal Infections | 1 | 2021 | 21 | 0.680 |
Why?
|
| Neisseria meningitidis | 2 | 2021 | 78 | 0.670 |
Why?
|
| Bioterrorism | 5 | 2008 | 13 | 0.670 |
Why?
|
| Materials Management, Hospital | 1 | 2020 | 2 | 0.650 |
Why?
|
| HIV-1 | 15 | 2002 | 723 | 0.640 |
Why?
|
| Ventilators, Mechanical | 1 | 2020 | 30 | 0.640 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 67 | 0.610 |
Why?
|
| Infection Control | 1 | 2020 | 105 | 0.590 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 313 | 0.580 |
Why?
|
| Bacterial Toxins | 4 | 2007 | 63 | 0.540 |
Why?
|
| Military Medicine | 2 | 2009 | 33 | 0.530 |
Why?
|
| Spinal Diseases | 1 | 2017 | 49 | 0.530 |
Why?
|
| Early Diagnosis | 1 | 2017 | 99 | 0.520 |
Why?
|
| Bacillus anthracis | 4 | 2011 | 11 | 0.520 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 210 | 0.510 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.510 |
Why?
|
| Clinical Protocols | 1 | 2017 | 135 | 0.510 |
Why?
|
| Mass Vaccination | 2 | 2014 | 10 | 0.500 |
Why?
|
| Medicare | 1 | 2020 | 611 | 0.490 |
Why?
|
| Models, Statistical | 1 | 2018 | 309 | 0.490 |
Why?
|
| Needles | 2 | 2013 | 70 | 0.480 |
Why?
|
| Virology | 2 | 2013 | 15 | 0.470 |
Why?
|
| Patient Care Team | 2 | 2017 | 340 | 0.470 |
Why?
|
| Military Personnel | 4 | 2009 | 120 | 0.460 |
Why?
|
| Humans | 58 | 2021 | 64238 | 0.450 |
Why?
|
| Antigens, Bacterial | 3 | 2007 | 200 | 0.450 |
Why?
|
| Pandemics | 1 | 2020 | 676 | 0.450 |
Why?
|
| Hospital Medicine | 1 | 2015 | 6 | 0.450 |
Why?
|
| Teaching Rounds | 1 | 2015 | 11 | 0.450 |
Why?
|
| Vaccination | 2 | 2015 | 371 | 0.440 |
Why?
|
| Poliomyelitis | 1 | 2014 | 3 | 0.430 |
Why?
|
| Disease Eradication | 1 | 2014 | 6 | 0.420 |
Why?
|
| Length of Stay | 1 | 2017 | 818 | 0.410 |
Why?
|
| HIV Infections | 10 | 2002 | 976 | 0.410 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 437 | 0.400 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1118 | 0.390 |
Why?
|
| Disease Outbreaks | 2 | 2012 | 116 | 0.380 |
Why?
|
| Tobacco Mosaic Virus | 1 | 2012 | 8 | 0.380 |
Why?
|
| Plant Diseases | 1 | 2012 | 12 | 0.370 |
Why?
|
| Proprotein Convertases | 1 | 2011 | 5 | 0.370 |
Why?
|
| Aging | 1 | 2018 | 754 | 0.370 |
Why?
|
| Physician's Role | 2 | 2003 | 124 | 0.360 |
Why?
|
| Vaccinia virus | 2 | 2008 | 73 | 0.350 |
Why?
|
| Sepsis | 1 | 2013 | 290 | 0.310 |
Why?
|
| History, 20th Century | 4 | 2012 | 235 | 0.310 |
Why?
|
| Communicable Diseases | 2 | 2011 | 91 | 0.300 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2013 | 29 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 2217 | 0.280 |
Why?
|
| Virulence Factors | 2 | 2007 | 85 | 0.270 |
Why?
|
| RNA, Viral | 4 | 2013 | 275 | 0.260 |
Why?
|
| Efficiency, Organizational | 2 | 2017 | 96 | 0.260 |
Why?
|
| Vaccinia | 1 | 2005 | 32 | 0.230 |
Why?
|
| Chloroquine | 1 | 2004 | 61 | 0.220 |
Why?
|
| United States | 8 | 2020 | 7923 | 0.210 |
Why?
|
| Botulinum Toxins | 1 | 2003 | 6 | 0.200 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 1997 | 137 | 0.200 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2003 | 9 | 0.200 |
Why?
|
| Africa South of the Sahara | 2 | 2014 | 21 | 0.200 |
Why?
|
| Influenza, Human | 4 | 2013 | 212 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 4 | 2018 | 800 | 0.180 |
Why?
|
| Vaccines, Conjugate | 1 | 2021 | 19 | 0.170 |
Why?
|
| Immunity, Mucosal | 3 | 1999 | 52 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 5 | 2012 | 518 | 0.170 |
Why?
|
| HIV Antibodies | 4 | 1999 | 148 | 0.170 |
Why?
|
| HIV Envelope Protein gp120 | 5 | 2002 | 134 | 0.170 |
Why?
|
| DNA Probes | 2 | 2012 | 35 | 0.160 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2020 | 5 | 0.160 |
Why?
|
| Federal Government | 1 | 2020 | 19 | 0.160 |
Why?
|
| Masks | 1 | 2020 | 23 | 0.160 |
Why?
|
| Government Regulation | 1 | 2020 | 41 | 0.160 |
Why?
|
| Skin | 1 | 2003 | 385 | 0.160 |
Why?
|
| Time Factors | 2 | 2017 | 3724 | 0.160 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2011 | 12 | 0.160 |
Why?
|
| Anti-Infective Agents | 2 | 2012 | 150 | 0.150 |
Why?
|
| History, 19th Century | 2 | 2012 | 42 | 0.150 |
Why?
|
| Endotoxins | 2 | 2010 | 82 | 0.150 |
Why?
|
| Hospitalization | 2 | 2017 | 1368 | 0.150 |
Why?
|
| Alpha-Globulins | 2 | 2011 | 5 | 0.140 |
Why?
|
| History, 21st Century | 2 | 2012 | 176 | 0.140 |
Why?
|
| Decision Making, Organizational | 1 | 2017 | 26 | 0.140 |
Why?
|
| Fever | 1 | 2018 | 66 | 0.140 |
Why?
|
| Back Pain | 1 | 2018 | 51 | 0.130 |
Why?
|
| Hospitals | 1 | 2020 | 390 | 0.130 |
Why?
|
| Patient Dropouts | 1 | 2017 | 49 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 438 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2020 | 6726 | 0.130 |
Why?
|
| Virus Diseases | 2 | 2012 | 123 | 0.130 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 2 | 2013 | 28 | 0.130 |
Why?
|
| Aged | 5 | 2020 | 14648 | 0.120 |
Why?
|
| Genes, nef | 1 | 1996 | 6 | 0.120 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2013 | 91 | 0.120 |
Why?
|
| Patient Admission | 1 | 2017 | 198 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 462 | 0.110 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 1995 | 4 | 0.110 |
Why?
|
| Contrast Media | 1 | 2017 | 429 | 0.110 |
Why?
|
| Mycobacterium haemophilum | 1 | 1994 | 5 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1162 | 0.110 |
Why?
|
| Mycobacterium Infections | 1 | 1994 | 16 | 0.110 |
Why?
|
| Molecular Sequence Data | 9 | 2011 | 1997 | 0.110 |
Why?
|
| Poliovirus | 1 | 2014 | 6 | 0.110 |
Why?
|
| Poliovirus Vaccines | 1 | 2014 | 4 | 0.110 |
Why?
|
| Health Education | 1 | 2015 | 190 | 0.110 |
Why?
|
| Massachusetts | 1 | 2020 | 2094 | 0.110 |
Why?
|
| Public Health Surveillance | 1 | 2014 | 28 | 0.100 |
Why?
|
| International Cooperation | 1 | 2014 | 90 | 0.100 |
Why?
|
| Female | 16 | 2018 | 33350 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2013 | 32 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2017 | 507 | 0.100 |
Why?
|
| Drug Industry | 1 | 2014 | 42 | 0.100 |
Why?
|
| Lipopolysaccharides | 3 | 2010 | 624 | 0.100 |
Why?
|
| Bacterial Vaccines | 2 | 2010 | 81 | 0.100 |
Why?
|
| Dacryocystitis | 1 | 1993 | 3 | 0.100 |
Why?
|
| Eye Infections, Bacterial | 1 | 1993 | 6 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 318 | 0.100 |
Why?
|
| Tracheal Diseases | 1 | 2013 | 12 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 34 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2015 | 1019 | 0.100 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1993 | 19 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 1995 | 417 | 0.100 |
Why?
|
| Adult | 16 | 2013 | 17116 | 0.100 |
Why?
|
| Male | 14 | 2018 | 30294 | 0.090 |
Why?
|
| Bacteriology | 1 | 2012 | 1 | 0.090 |
Why?
|
| Antitoxins | 1 | 2012 | 2 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 544 | 0.090 |
Why?
|
| Thailand | 6 | 1999 | 98 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 35 | 0.090 |
Why?
|
| Phylogeny | 4 | 1998 | 385 | 0.090 |
Why?
|
| Base Sequence | 5 | 2011 | 1332 | 0.090 |
Why?
|
| Viruses | 1 | 2012 | 81 | 0.090 |
Why?
|
| Herpesvirus 1, Cercopithecine | 1 | 1991 | 1 | 0.090 |
Why?
|
| Veterinary Medicine | 1 | 1991 | 5 | 0.090 |
Why?
|
| Herpesviridae Infections | 1 | 1991 | 27 | 0.090 |
Why?
|
| Research | 1 | 2012 | 196 | 0.080 |
Why?
|
| Disaster Planning | 2 | 2008 | 58 | 0.080 |
Why?
|
| Spleen | 3 | 2011 | 482 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 771 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2005 | 2176 | 0.080 |
Why?
|
| Tularemia | 1 | 2010 | 15 | 0.080 |
Why?
|
| Francisella tularensis | 1 | 2010 | 21 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2012 | 265 | 0.080 |
Why?
|
| Biological Warfare Agents | 1 | 2008 | 2 | 0.070 |
Why?
|
| Middle Aged | 6 | 2018 | 17898 | 0.070 |
Why?
|
| Occupational Diseases | 1 | 1991 | 267 | 0.070 |
Why?
|
| Rescue Work | 1 | 2008 | 15 | 0.070 |
Why?
|
| RNA | 1 | 2012 | 429 | 0.070 |
Why?
|
| Vaccines, Attenuated | 1 | 2008 | 36 | 0.070 |
Why?
|
| Cyclonic Storms | 1 | 2008 | 23 | 0.070 |
Why?
|
| Sex Work | 2 | 1999 | 21 | 0.070 |
Why?
|
| Disaster Medicine | 1 | 2008 | 8 | 0.070 |
Why?
|
| Macrophages, Peritoneal | 2 | 2005 | 77 | 0.070 |
Why?
|
| Frail Elderly | 1 | 2008 | 107 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2010 | 587 | 0.070 |
Why?
|
| Animals | 9 | 2011 | 20961 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 891 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 984 | 0.070 |
Why?
|
| Inflammation | 1 | 2013 | 1162 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 883 | 0.060 |
Why?
|
| Internal Medicine | 1 | 2008 | 163 | 0.060 |
Why?
|
| Immunoglobulin A | 3 | 2010 | 98 | 0.060 |
Why?
|
| Furin | 1 | 2005 | 11 | 0.060 |
Why?
|
| Pericarditis | 1 | 2005 | 10 | 0.060 |
Why?
|
| History, 18th Century | 1 | 2005 | 9 | 0.060 |
Why?
|
| Amino Acid Sequence | 6 | 1998 | 1597 | 0.060 |
Why?
|
| Neutralization Tests | 1 | 2005 | 127 | 0.060 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2004 | 42 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2008 | 350 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 2010 | 463 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2004 | 99 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2011 | 749 | 0.050 |
Why?
|
| Child | 1 | 2014 | 4583 | 0.050 |
Why?
|
| Young Adult | 1 | 2014 | 4776 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2005 | 744 | 0.050 |
Why?
|
| Cell Death | 1 | 2004 | 286 | 0.050 |
Why?
|
| Rats | 1 | 2007 | 2005 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 329 | 0.050 |
Why?
|
| Cell Survival | 1 | 2004 | 582 | 0.050 |
Why?
|
| Soft Tissue Infections | 1 | 2003 | 48 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 869 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2008 | 672 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 356 | 0.050 |
Why?
|
| Botulism | 1 | 2002 | 1 | 0.050 |
Why?
|
| Chronic Disease | 3 | 2013 | 756 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2005 | 270 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2002 | 96 | 0.050 |
Why?
|
| Neutrophils | 1 | 2004 | 378 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 1997 | 458 | 0.040 |
Why?
|
| Neoplasms | 1 | 2011 | 1392 | 0.040 |
Why?
|
| HIV Envelope Protein gp160 | 2 | 1999 | 6 | 0.040 |
Why?
|
| Mice | 4 | 2011 | 11003 | 0.040 |
Why?
|
| DNA, Viral | 3 | 1996 | 234 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2002 | 153 | 0.040 |
Why?
|
| Cervix Uteri | 2 | 1999 | 61 | 0.040 |
Why?
|
| Asia | 2 | 1996 | 27 | 0.040 |
Why?
|
| Internet | 1 | 2003 | 467 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 1999 | 59 | 0.040 |
Why?
|
| Travel | 2 | 1995 | 44 | 0.040 |
Why?
|
| Sexual Behavior | 2 | 1999 | 195 | 0.030 |
Why?
|
| Nasal Mucosa | 1 | 1997 | 18 | 0.030 |
Why?
|
| Parotid Gland | 1 | 1997 | 11 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 2238 | 0.030 |
Why?
|
| Genitalia, Female | 1 | 1997 | 17 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1997 | 115 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1997 | 76 | 0.030 |
Why?
|
| Genes, gag | 1 | 1996 | 11 | 0.030 |
Why?
|
| Genes, env | 1 | 1996 | 16 | 0.030 |
Why?
|
| Mosaicism | 1 | 1996 | 30 | 0.030 |
Why?
|
| Adolescent | 2 | 2005 | 6304 | 0.030 |
Why?
|
| Uruguay | 1 | 1995 | 1 | 0.030 |
Why?
|
| Cambodia | 1 | 1995 | 27 | 0.030 |
Why?
|
| Liver | 2 | 2011 | 868 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 1996 | 102 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 365 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 1994 | 32 | 0.030 |
Why?
|
| Rifampin | 1 | 1994 | 25 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 1994 | 26 | 0.030 |
Why?
|
| ADP Ribose Transferases | 1 | 1994 | 63 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1994 | 53 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 386 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2005 | 5691 | 0.030 |
Why?
|
| Abscess | 1 | 1994 | 80 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1995 | 245 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 1994 | 89 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 2013 | 42 | 0.030 |
Why?
|
| Fatty Acids | 1 | 1994 | 202 | 0.030 |
Why?
|
| Dacryocystorhinostomy | 1 | 1993 | 2 | 0.030 |
Why?
|
| Nasolacrimal Duct | 1 | 1993 | 2 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1995 | 416 | 0.030 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1993 | 8 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1994 | 467 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 1994 | 268 | 0.020 |
Why?
|
| Antibodies, Bacterial | 2 | 2010 | 182 | 0.020 |
Why?
|
| Pulmonary Ventilation | 1 | 2013 | 38 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 2013 | 38 | 0.020 |
Why?
|
| Seasons | 1 | 2013 | 138 | 0.020 |
Why?
|
| Spirometry | 1 | 2013 | 112 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.020 |
Why?
|
| Genetic Variation | 1 | 1995 | 387 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2013 | 90 | 0.020 |
Why?
|
| Anaplasmataceae | 1 | 1992 | 1 | 0.020 |
Why?
|
| Rickettsiaceae Infections | 1 | 1992 | 5 | 0.020 |
Why?
|
| Arachnid Vectors | 1 | 1992 | 9 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 2013 | 107 | 0.020 |
Why?
|
| DNA Ligases | 1 | 2012 | 4 | 0.020 |
Why?
|
| Ligase Chain Reaction | 1 | 2012 | 2 | 0.020 |
Why?
|
| Ticks | 1 | 1992 | 36 | 0.020 |
Why?
|
| Prevalence | 1 | 1995 | 1407 | 0.020 |
Why?
|
| Aza Compounds | 1 | 2011 | 4 | 0.020 |
Why?
|
| Quinolines | 1 | 2011 | 48 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 34 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 266 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 27 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 59 | 0.020 |
Why?
|
| Limulus Test | 1 | 1989 | 1 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 1991 | 256 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2010 | 93 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 1989 | 13 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 1989 | 11 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2011 | 238 | 0.020 |
Why?
|
| Algorithms | 1 | 1995 | 1028 | 0.020 |
Why?
|
| Escherichia coli | 1 | 1994 | 718 | 0.020 |
Why?
|
| Temperature | 1 | 2011 | 312 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 497 | 0.020 |
Why?
|
| HIV Seronegativity | 2 | 1999 | 19 | 0.020 |
Why?
|
| Louisiana | 1 | 2008 | 17 | 0.020 |
Why?
|
| Florida | 1 | 2008 | 49 | 0.020 |
Why?
|
| Hybridization, Genetic | 1 | 2008 | 14 | 0.020 |
Why?
|
| Molecular Epidemiology | 2 | 1998 | 32 | 0.020 |
Why?
|
| Competency-Based Education | 1 | 2008 | 30 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2008 | 37 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2008 | 199 | 0.020 |
Why?
|
| Patient Simulation | 1 | 2008 | 72 | 0.020 |
Why?
|
| Genotype | 2 | 1999 | 668 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 964 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2010 | 775 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2002 | 102 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2002 | 147 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2008 | 808 | 0.010 |
Why?
|
| Needle Sharing | 1 | 1999 | 15 | 0.010 |
Why?
|
| Malaysia | 1 | 1998 | 2 | 0.010 |
Why?
|
| Body Fluids | 1 | 1999 | 21 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 1999 | 27 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 1999 | 53 | 0.010 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 1999 | 22 | 0.010 |
Why?
|
| Risk Factors | 2 | 1999 | 5339 | 0.010 |
Why?
|
| Vagina | 1 | 1999 | 87 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 5520 | 0.010 |
Why?
|
| Korea | 1 | 1997 | 9 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1997 | 93 | 0.010 |
Why?
|
| Serotyping | 1 | 1996 | 53 | 0.010 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 1996 | 15 | 0.010 |
Why?
|
| Genes, pol | 1 | 1996 | 1 | 0.010 |
Why?
|
| HIV Long Terminal Repeat | 1 | 1996 | 12 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1996 | 30 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1996 | 112 | 0.010 |
Why?
|
| Africa | 1 | 1996 | 29 | 0.010 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 1996 | 28 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1996 | 84 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1996 | 110 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1999 | 1130 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1996 | 151 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1999 | 1272 | 0.010 |
Why?
|
| O Antigens | 1 | 1994 | 5 | 0.010 |
Why?
|
| Exotoxins | 1 | 1994 | 9 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1994 | 46 | 0.010 |
Why?
|
| NF-kappa B | 1 | 1996 | 471 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1994 | 114 | 0.010 |
Why?
|
| Binding Sites | 1 | 1996 | 914 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1996 | 685 | 0.010 |
Why?
|
| Peptides | 1 | 1996 | 590 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 495 | 0.010 |
Why?
|
| Cohort Studies | 1 | 1999 | 2604 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1997 | 3315 | 0.000 |
Why?
|